6533b858fe1ef96bd12b6573
RESEARCH PRODUCT
Fertility sparing treatments in endometrial cancer patients: the potential role of the new molecular classification
G VizzielliFabrizio SignoreFederica PerelliGiovanni ScambiaMarco D'indinosanteMarco GiustiAnna Franca CavaliereGiuseppe GulloAlberto MatteiAnnalisa VidiriSimona ZaamiIrene Turrinisubject
Oncologymedicine.medical_specialtyQH301-705.5obstetric outcomesReviewHysteroscopyCatalysisFertility sparing surgeryInorganic ChemistryMolecular classificationPrognostic classificationInternal medicineCancer genomeOutcome Assessment Health CaremedicineHumansmolecular biologyPhysical and Theoretical ChemistryBiology (General)QD1-999SpectroscopyPregnancybusiness.industryEndometrial cancerOrganic ChemistryFertility PreservationCancerGeneral Medicinemedicine.diseaseEndometrial cancer; Fertility sparing; Molecular biology; Obstetric outcomes; PregnancyCombined Modality Therapyfertility sparingEndometrial NeoplasmsComputer Science Applicationsendometrial cancer; molecular biology; fertility sparing; obstetric outcomes; pregnancyChemistryFertilityGynecological malignancyendometrial cancerFemalepregnancyProgestinsbusinessOrgan Sparing Treatmentsdescription
Endometrial cancer is the most frequent gynecological malignancy, and, although epidemiologically it mainly affects advanced age women, it can also affect young patients who want children and who have not yet completed their procreative project. Fertility sparing treatments are the subject of many studies and research in continuous evolution, and represent a light of hope for young cancer patients who find themselves having to face an oncological path before fulfilling their desire for motherhood. The advances in molecular biology and the more precise clinical and prognostic classification of endometrial cancer based on the 2013 The Cancer Genome Atlas classification allow for the selection of patients who can be submitted to fertility sparing treatments with increasing oncological safety. It would also be possible to predict the response to hormonal treatment by investigating the state of the genes of the mismatch repair.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-11-01 |